Get the Stockscreener App
117.36
4.89%
5.47
Pre-market:
116.36
-1.00
-0.85%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc stock is traded at $117.36, with a volume of 104.48K.
It is up +4.89% in the last 24 hours and up +2.37% over the past month.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
See More
Previous Close:
$111.89
Open:
$113.01
24h Volume:
104.48K
Relative Volume:
0.89
Market Cap:
$2.22B
Revenue:
$152.42M
Net Income/Loss:
$45.24M
P/E Ratio:
46.76
EPS:
2.51
Net Cash Flow:
$6.97M
1W Performance:
+8.12%
1M Performance:
+2.37%
6M Performance:
+17.64%
1Y Performance:
+61.83%
1-Day Range:
$112.53
$117.53
1-Week Range:
$107.99
$117.53
52-Week Range:
$67.72
$129.90
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals Inc
Sector
Industry
Phone
858-550-7500
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
117.36 | 2.22B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Resumed | Stephens | Overweight |
| Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-06-20 | Initiated | Barclays | Overweight |
| Mar-24-20 | Downgrade | Argus | Buy → Hold |
| Mar-10-20 | Initiated | Guggenheim | Neutral |
| Feb-06-20 | Initiated | The Benchmark Company | Buy |
| Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-03-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-18 | Reiterated | Argus | Buy |
| Aug-17-18 | Initiated | Goldman | Neutral |
| Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-21-18 | Initiated | Argus | Buy |
| Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-17 | Resumed | H.C. Wainwright | Buy |
| Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-11-16 | Initiated | Sidoti | Buy |
| Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
Burney Co. Grows Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
JPMorgan Chase & Co. Lowers Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Position Lowered by JPMorgan Chase & Co. - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Recommendation of “Buy” by Brokerages - Defense World
LGND (Ligand Pharmaceuticals) Debt-to-EBITDA : 0.54 (As of Sep. 2024) - GuruFocus.com
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
Don't Ignore The Insider Selling In Ligand Pharmaceuticals - Simply Wall St
Principal Financial Group Inc. Boosts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Is Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Recent Price Movement Underpinned By Its Weak Fundamentals? - Simply Wall St
Jane Street Group LLC Sells 7,790 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Jane Street Group LLC Trims Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Octavio Espinoza Executes Sell Order: Offloads $244K In Ligand Pharmaceuticals Stock - Benzinga
Ligand Pharmaceuticals (NASDAQ:LGND) Updates FY 2024 Earnings Guidance - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) shareholders have earned a 59% return over the last year - Yahoo Finance
MML Investors Services LLC Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Insider Sell Alert: Octavio Espinoza Sells Shares of Ligand Pharmaceuticals Inc (LGND) - GuruFocus.com
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) CFO Octavio Espinoza Sells 2,104 Shares - MarketBeat
Ligand Pharmaceuticals CFO Espinoza sells $244,850 in stock By Investing.com - Investing.com Canada
Benchmark maintains Buy on Ligand Pharma stock citing consistent financial performance - Investing.com Canada
Geode Capital Management LLC Acquires 22,495 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Holdings Raised by Geode Capital Management LLC - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Receives “Buy” Rating from Benchmark - Defense World
Benchmark Reaffirms Buy Rating for Ligand Pharmaceuticals (NASDAQ:LGND) - MarketBeat
Franklin Resources Inc. Has $9.79 Million Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Barclays PLC Has $4.35 Million Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Stifel Financial Corp Raises Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Holdings Lifted by HighTower Advisors LLC - Defense World
Wellington Management Group LLP Decreases Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
What is Zacks Small Cap's Forecast for LGND FY2025 Earnings? - MarketBeat
Zacks Small Cap Issues Optimistic Estimate for LGND Earnings - Defense World
Zacks Small Cap Has Strong Estimate for LGND FY2026 Earnings - MarketBeat
Fmr LLC Raises Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Ligand Pharmaceuticals: A Strong Growth Trajectory with Impressive Returns and Strategic Advancements - mediahousepress
LGND: 2025 View Calls for 17% Topline Growth - Zacks Small Cap Research
Ligand Pharmaceuticals' SWOT analysis: diversified royalty model drives stock growth - Investing.com Australia
Barclays Boosts Ligand Pharmaceuticals (NASDAQ:LGND) Price Target to $160.00 - MarketBeat
Ligand Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Ligand Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com India
BNP Paribas Financial Markets Sells 1,586 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals' SWOT analysis: royalty aggregator stock poised for growth - Investing.com
What is HC Wainwright's Estimate for LGND FY2025 Earnings? - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 6,031 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
The Manufacturers Life Insurance Company Sells 167 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand price target raised to $151 from $135 at Oppenheimer - Yahoo Finance
Ligand Pharmaceuticals Inc Stock (LGND) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):